|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4537776A
(en)
|
1983-06-21 |
1985-08-27 |
The Procter & Gamble Company |
Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
ATE122238T1
(de)
|
1987-06-10 |
1995-05-15 |
Dana Farber Cancer Inst Inc |
Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
EP0786469B1
(en)
|
1990-06-11 |
2006-03-01 |
Gilead Sciences, Inc. |
Methods of use of nucleic acid ligands
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
AU701578B2
(en)
|
1992-08-21 |
1999-02-04 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
WO1996002561A1
(en)
|
1994-07-20 |
1996-02-01 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
EP0739981A1
(en)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
|
AU6961796A
(en)
|
1995-09-12 |
1997-04-01 |
Chiron Corporation |
Improved interleukin-6 receptor antagonist
|
|
EP0770397B1
(en)
|
1995-10-18 |
2004-04-21 |
Akzo Nobel N.V. |
Newcastle disease virus combination vaccine
|
|
US5986059A
(en)
|
1996-06-14 |
1999-11-16 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
WO1999037681A2
(en)
|
1998-01-26 |
1999-07-29 |
Unilever Plc |
Method for producing antibody fragments
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
DK1656952T3
(da)
|
1998-10-16 |
2014-01-20 |
Biogen Idec Inc |
Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
DE60013767T3
(de)
|
1999-01-19 |
2009-07-09 |
Unilever N.V. |
Verfahren zur herstellung von antikörperfragmenten
|
|
EP1696038B1
(en)
|
1999-05-05 |
2010-06-02 |
Phylogica Limited |
Isolating biological modulators from biodiverse gene fragment libraries
|
|
AU4761100A
(en)
|
1999-05-26 |
2000-12-18 |
Kalle Saksela |
Methods and materials for generating sh3 domains with tailored binding properties
|
|
SE0001877D0
(sv)
|
2000-05-22 |
2000-05-22 |
Klaus Mosbach |
Molecular imprinting
|
|
WO2001090190A2
(en)
|
2000-05-26 |
2001-11-29 |
National Research Council Of Canada |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
|
DE60142479D1
(de)
|
2000-08-30 |
2010-08-12 |
Penn State Res Found |
Aminosäureaustauschmutanten von interleukin 13
|
|
DE60140474D1
(de)
|
2000-09-08 |
2009-12-24 |
Univ Zuerich |
Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
|
|
DE10053224A1
(de)
|
2000-10-26 |
2002-05-08 |
Univ Goettingen Georg August |
Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
|
|
US20040132094A1
(en)
|
2000-12-13 |
2004-07-08 |
Michael Etzerodt |
Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
RU2004109222A
(ru)
|
2001-08-30 |
2005-10-20 |
Байорексис Фармасьютикал Корпорейшн (Us) |
Слитые белки модифицированного трансферрина
|
|
EP1433793A4
(en)
|
2001-09-13 |
2006-01-25 |
Inst Antibodies Co Ltd |
METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
|
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
CA2501295A1
(en)
|
2002-10-02 |
2004-04-15 |
Jack Nguyen |
Methods of generating and screening for proteases with altered specificity
|
|
CA2505316C
(en)
|
2002-11-08 |
2014-08-05 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
GB0228210D0
(en)
|
2002-12-03 |
2003-01-08 |
Babraham Inst |
Single chain antibodies
|
|
WO2004060965A2
(en)
|
2002-12-31 |
2004-07-22 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
|
DK1587907T3
(da)
|
2003-01-07 |
2011-04-04 |
Dyax Corp |
Kunitz-domænebibliotek
|
|
TW200526780A
(en)
|
2004-01-06 |
2005-08-16 |
Hayashibara Biochem Lab |
TNF antagonists and TNF inhibitors comprising the same as the active ingredient
|
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
|
DE102004049479A1
(de)
|
2004-10-11 |
2006-04-13 |
Scil Proteins Gmbh |
Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
WO2006122787A1
(en)
|
2005-05-18 |
2006-11-23 |
Ablynx Nv |
Serum albumin binding proteins
|
|
EP1943257A2
(en)
|
2005-05-19 |
2008-07-16 |
Genentech, Inc. |
Fibroblast activation protein inhibitor compounds and methods
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
TW200732347A
(en)
|
2005-10-06 |
2007-09-01 |
Trophogen Inc |
VEGF analogs and methods of use
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
EP1892248A1
(en)
|
2006-08-21 |
2008-02-27 |
Eidgenössische Technische Hochschule Zürich |
Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
|
|
EP2102241A2
(en)
|
2006-12-15 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences that modulate the interaction between cells of the immune system
|
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
|
US11535673B2
(en)
|
2007-04-05 |
2022-12-27 |
President and Fellows of Harvard CoHege |
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
|
|
CN101835802B
(zh)
|
2007-06-01 |
2014-04-09 |
马里兰大学巴尔的摩分校 |
免疫球蛋白恒定区Fc受体结合剂
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
CN101412015B
(zh)
|
2007-10-19 |
2011-08-31 |
深圳富泰宏精密工业有限公司 |
夹具及应用该夹具的挂具结构
|
|
EP2109690B9
(en)
|
2007-11-29 |
2012-10-24 |
MOLECULAR HEALTH GmbH |
Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use.
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010030671A1
(en)
|
2008-09-09 |
2010-03-18 |
University Of Medicine And Dentistry Of New Jersey |
Type i interferon antagonists
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
EP2483316A1
(en)
|
2009-10-02 |
2012-08-08 |
Ludwig Institute for Cancer Research Ltd. |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
US20110262348A1
(en)
|
2010-03-29 |
2011-10-27 |
Vrije Universiteit Brussel |
Selective targeting of intratumoral cells
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
SG10201603411WA
(en)
|
2011-10-28 |
2016-07-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
CN104245734B
(zh)
|
2012-01-20 |
2017-09-05 |
非营利性组织佛兰芒综合大学生物技术研究所 |
靶向突变体α‑螺旋束细胞因子
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
CA2904969C
(en)
|
2013-03-13 |
2025-06-17 |
Imaginab, Inc. |
DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
|
|
US20160145325A1
(en)
|
2013-04-29 |
2016-05-26 |
Agrosavfe N.V. |
Agrochemical compositions comprising antibodies binding to sphingolipids
|
|
WO2015007536A2
(en)
|
2013-07-18 |
2015-01-22 |
Vib Vzw |
Fusokines involving cytokines with strongly reduced receptor binding affinities
|
|
DK3022226T3
(en)
|
2013-07-19 |
2019-03-25 |
Vib Vzw |
TARGETED MODIFIED IL-1 FAMILY MEMBERS
|
|
CA2918119C
(en)
|
2013-07-19 |
2022-11-29 |
Centre Hospitalier Regional Universitaire De Montpellier |
Targeting of ifn.alpha.2 antagonists to treat autoimmune diseases
|
|
JP6595988B2
(ja)
|
2013-07-19 |
2019-10-23 |
ヴィブ ブイゼットダブリュー |
ターゲットされる修飾ｔｎｆファミリーメンバー
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3168717A4
(en)
|
2014-07-11 |
2018-03-14 |
Wacom Co., Ltd. |
Position indicator, position detection device, and input control method for position detection device
|
|
US10435470B2
(en)
|
2014-08-05 |
2019-10-08 |
Cb Therapeutics, Inc. |
Anti-PD-L1 antibodies
|
|
WO2016025385A1
(en)
|
2014-08-11 |
2016-02-18 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
MY193723A
(en)
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
CA2973040A1
(en)
|
2015-01-09 |
2016-07-14 |
Mabimmune Diagnostics Ag |
Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
|
|
GB201500463D0
(en)
|
2015-01-12 |
2015-02-25 |
Cresendo Biolog Ltd |
Therapeutic molecules
|
|
GB201500461D0
(en)
|
2015-01-12 |
2015-02-25 |
Cresendo Biolog Ltd |
Therapeutic molecules
|
|
US10669350B2
(en)
|
2015-02-02 |
2020-06-02 |
Georg Bauer |
Antigen-binding constructs that bind to and inhibit catalase and/or superoxide dismutase as well as pharmaceutical compositions containing them for tumor therapy
|
|
JP2018511303A
(ja)
|
2015-02-04 |
2018-04-26 |
アブセレックス テクノロジーズ インコーポレイテッド |
抗サルモネラ抗体及びその使用
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
CN106928363B
(zh)
*
|
2015-12-30 |
2020-09-25 |
广西医科大学 |
一种FAP纳米抗体Nb12
|
|
US11001631B2
(en)
|
2016-02-05 |
2021-05-11 |
Orionis Biosciences BV |
Clec9A binding agents
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ |
新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
|
|
CA3040802A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
EP3577133A1
(en)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Targeted chimeric proteins and uses thereof
|
|
EP3580230B1
(en)
|
2017-02-07 |
2026-04-22 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
EP3638700B8
(en)
*
|
2017-06-14 |
2024-09-04 |
Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation |
Proteinaceous heterodimer and use thereof
|
|
EP3665201A4
(en)
|
2017-08-09 |
2021-06-02 |
Orionis Biosciences, Inc. |
CD8 BINDERS
|
|
US12091463B2
(en)
|
2017-08-09 |
2024-09-17 |
Orionis Biosciences, Inc. |
Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
|
|
JP7423511B2
(ja)
|
2017-08-09 |
2024-01-29 |
オリオンズ バイオサイエンス インコーポレイテッド |
Ｐｄ－１およびｐｄ－ｌ１結合物質
|
|
US20200354424A1
(en)
|
2018-01-26 |
2020-11-12 |
Orionis Biosciences, Inc. |
Xcr1 binding agents and uses thereof
|
|
US20210024631A1
(en)
|
2018-03-28 |
2021-01-28 |
Orionis Biosciences, Inc. |
Bi-functional proteins and construction thereof
|
|
WO2020033646A1
(en)
|
2018-08-08 |
2020-02-13 |
Orionis Biosciences, Inc. |
SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
CA3125527A1
(en)
|
2018-12-20 |
2020-06-25 |
Orionis Biosciences, Inc. |
Particle based small molecule-protein complex trap
|
|
JP7689079B2
(ja)
|
2019-03-28 |
2025-06-05 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
治療用インターフェロンアルファ１タンパク質
|
|
JP7729778B2
(ja)
|
2019-03-28 |
2025-08-26 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体
|
|
CA3133648A1
(en)
|
2019-03-28 |
2020-10-01 |
Orionis Biosciences, Inc. |
Fibroblast activation protein binding agents and use thereof
|
|
CN120590542A
(zh)
|
2019-03-28 |
2025-09-05 |
奥里尼斯生物科学股份有限公司 |
基于clec9a的嵌合蛋白复合物
|
|
WO2020198659A1
(en)
|
2019-03-28 |
2020-10-01 |
Orionis Biosciences, Inc. |
Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins
|
|
WO2020257412A1
(en)
|
2019-06-19 |
2020-12-24 |
Orionis Biosciences, Inc. |
Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
|